Literature DB >> 11465420

Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS).

H Hirabayashi1, T Sawamoto, J Fujisaki, Y Tokunaga, S Kimura, T Hata.   

Abstract

PURPOSE: The objective of this investigation is to develop a rational design of Osteotropic Drug Delivery System (ODDS), which we have proposed as a novel method for drug delivery to the skeleton via bisphosphonic prodrug, based on the relationship between physicochemical and pharmacokinetic properties of bisphosphonates.
METHODS: The theoretical octanol/water partition coefficients (clog P) of 13 bisphosphonates were calculated by computer software, CLOGP ver. 3.05 (Daylight C.I.S., Inc. Irvine, CA) and related to pharmacokinetic or osteotropic parameters after intravenous injection into rats. On the other hand, to optimize ODDS of diclofenac (DIC-BP), the effects of doses or infusion rates on the in vivo disposition were investigated in relation to solubility product value (Ksp) of DIC-BP-calcium complex.
RESULTS: Clog P had good correlations with total plasma clearance, apparent distribution volume and the fraction dose delivered to the whole skeleton after bolus injection into rats (r = -0.868 approximately -0.914). The targetability of bisphosphonates to the skeleton was linearly decreased with an increase in clog P value and the more hydrophilic bisphosphonates were suitable for ODDS in bolus administration. On the other hand, DIC-BP, a relatively lipophilic bisphosphonate, was effectively and selectively delivered to the skeleton only when administered as a slow infusion to keep plasma concentration lower than that calculated from Ksp value where DIC-BP could precipitate with calcium in the plasma circulation.
CONCLUSIONS: Our results suggest the possibility of a rational design of ODDS via bisphosphonic prodrugs, after consideration of compound lipophilicity and precipitability of bisphosphonate-calcium complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465420     DOI: 10.1023/a:1011033326980

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives.

Authors:  S Bisaz; A Jung; H Fleisch
Journal:  Clin Sci Mol Med       Date:  1978-03

Review 2.  Strategies and recent technologies in drug discovery.

Authors:  H Kubinyi
Journal:  Pharmazie       Date:  1995-10       Impact factor: 1.267

Review 3.  Treatment of Paget's disease of bone.

Authors:  J A Cantrill; D C Anderson
Journal:  Clin Endocrinol (Oxf)       Date:  1990-04       Impact factor: 3.478

4.  Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: Pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein.

Authors:  J Fujisaki; Y Tokunaga; T Sawamoto; T Takahashi; S Kimura; F Shimojo; T Hata
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

5.  Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

Authors:  E Van Beek; C Löwik; I Que; S Papapoulos
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

Review 6.  [Development of quantitative structure-activity relationships and computer-aided drug design].

Authors:  I Moriguchi
Journal:  Yakugaku Zasshi       Date:  1994-03       Impact factor: 0.302

7.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

8.  Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.

Authors:  N Sawyer; C Newstead; A Drummond; J Cunningham
Journal:  Bone Miner       Date:  1990-05

9.  Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.

Authors:  J H Lin; I W Chen; F A deLuna; M Hichens
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030

Review 10.  Development of quantitative structure-pharmacokinetic relationships.

Authors:  J M Mayer; H van de Waterbeemd
Journal:  Environ Health Perspect       Date:  1985-09       Impact factor: 9.031

View more
  7 in total

1.  Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.

Authors:  Cammy K-M Chen; Michael P Hudock; Yonghui Zhang; Rey-Ting Guo; Rong Cao; Joo Hwan No; Po-Huang Liang; Tzu-Ping Ko; Tao-Hsin Chang; Shiou-Chi Chang; Yongcheng Song; Jordan Axelson; Anup Kumar; Andrew H-J Wang; Eric Oldfield
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 2.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.

Authors:  Yonghui Zhang; Rong Cao; Fenglin Yin; Michael P Hudock; Rey-Ting Guo; Kilannin Krysiak; Sujoy Mukherjee; Yi-Gui Gao; Howard Robinson; Yongcheng Song; Joo Hwan No; Kyle Bergan; Annette Leon; Lauren Cass; Amanda Goddard; Ting-Kai Chang; Fu-Yang Lin; Ermond Van Beek; Socrates Papapoulos; Andrew H-J Wang; Tadahiko Kubo; Mitsuo Ochi; Dushyant Mukkamala; Eric Oldfield
Journal:  J Am Chem Soc       Date:  2009-04-15       Impact factor: 15.419

4.  Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators.

Authors:  Yonghui Zhang; Rong Cao; Fenglin Yin; Fu-Yang Lin; Hong Wang; Kilannin Krysiak; Joo-Hwan No; Dushyant Mukkamala; Kevin Houlihan; Jikun Li; Craig T Morita; Eric Oldfield
Journal:  Angew Chem Int Ed Engl       Date:  2010-02-01       Impact factor: 15.336

5.  Systematic study of the physicochemical properties of a homologous series of aminobisphosphonates.

Authors:  Aino-Liisa Saari; Helena Hyvönen; Manu Lahtinen; Markku Ylisirniö; Petri Turhanen; Erkki Kolehmainen; Sirpa Peräniemi; Jouko Vepsäläinen
Journal:  Molecules       Date:  2012-09-12       Impact factor: 4.411

6.  Harnessing the power of antibodies to fight bone metastasis.

Authors:  Zeru Tian; Ling Wu; Chenfei Yu; Yuda Chen; Zhan Xu; Igor Bado; Axel Loredo; Lushun Wang; Hai Wang; Kuan-Lin Wu; Weijie Zhang; Xiang H-F Zhang; Han Xiao
Journal:  Sci Adv       Date:  2021-06-23       Impact factor: 14.957

7.  Preparation of mixed trialkyl alkylcarbonate derivatives of etidronic acid via an unusual route.

Authors:  Petri A Turhanen; Janne Weisell; Jouko J Vepsäläinen
Journal:  Beilstein J Org Chem       Date:  2012-11-20       Impact factor: 2.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.